BioSpace News Archive

Arbutus Biopharma Corporation today announced that it has scheduled its first quarter 2023 financial results and corporate update for Thursday, May 4, 2023.

Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced its co-founder and Chief Operating Officer (COO), Dr. Howard Lewin, will take part in a virtual event hosted by Truist Securities on Friday, April 21, 2023, at 3:30 p.m. ET.

Blue Water Vaccines Inc. today announced the signing of an Asset Purchase Agreement (the “Agreement”) with Veru Inc. (“Veru”) for the purchase of ENTADFI®.

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 2023.

Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

ProQR Therapeutics NV. announced that Company management will participate in the following upcoming investor conferences and events.

Collegium Pharmaceutical, Inc. announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the Stifel 2023 Virtual Targeted Oncology Days, taking place April 25-26, 2023.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for advanced heart failure patients.

Aquestive Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Anaphylm™ as the proposed brand name for AQST-109, the Company’s polymer matrix-based epinephrine prodrug administered as a sublingual film in development for the treatment of severe allergic reactions including anaphylaxis.